Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.56 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.55 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydrolipoic Acid SCHEMBL19773 | 1.00 | FOLH1 (0.56) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL1115003 | 1.00 | FOLH1 (0.56) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL867951 | 1.00 | FOLH1 (0.56) | FOLH1GSTK1ENPEPLMNAANPEP | |
| SCHEMBL6805309 | 0.98 | GSTK1 (0.57) | FOLH1GSTK1ENPEPLMNAANPEP | |
| SCHEMBL21611884 | 0.98 | GSTK1 (0.57) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL2582098 | 0.98 | FOLH1 (0.54) | FOLH1GSTK1ENPEPLMNAANPEP | |
| SCHEMBL6809842 | 0.98 | GSTK1 (0.57) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL2578740 | 0.98 | FOLH1 (0.54) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL19359055 | 0.98 | FOLH1 (0.54) | FOLH1GSTK1ENPEPLMNAANPEP | |
| Dihydrolipoic Acid SCHEMBL4761911 | 0.96 | FOLH1 (0.52) | FOLH1GSTK1ENPEPLMNAANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778576-B | Stabilized anthocyanin compositions | 欧博康有限公司 | 2017-07-21 | — | — | CN | disclosed |
| EP-2442645-A1 | CHOLINE ESTERS | Encore Health, Llc (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120039814-A1 | Topical Compositions and Methods of Detection and Treatment | JOHNS HOPKINS UNIVERSITY | 2012-02-16 | — | — | US | disclosed |
| US-8034833-B2 | Phosphorus binder for treatment of renal disease | BIOLINK LIFE SCIENCES, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2364084-A1 | LOW DOSE LIPOIC ACID PHARMACEUTICAL COMPOSITIONS AND METHODS | Encore Health, Llc (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110160305-A1 | Oral Delivery of Therapeutic Doses of Glutathione | AGB INNOVATIONS, LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110098347-A1 | PHOSPHOROUS BINDER FOR TREATMENT OF KIDNEY DISEASE | BIOLINK LIFE SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7862836-B2 | Phosphorus binder for treatment of kidney disease | BIOLINK LIFE SCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039814-A1 | Topical Compositions and Methods of Detection and Treatment | LIPA, TSLP, CUTA | FOLH1 559/4885GSTK1 1087/4885ENPEP 1150/4885 |
| US-20110098347-A1 | PHOSPHOROUS BINDER FOR TREATMENT OF KIDNEY DISEASE | ALPI, PHPT1, FABP2 | FOLH1 630/4885GSTK1 3334/4885ENPEP 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.